Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to HUMIRA*

Newswire.ca - Thu Oct 26, 2023

KIRKLAND, QC, Oct. 26, 2023 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced the availability of HADLIMA^®(adalimumab), a biosimilar for Humira* (adalimumab), in a high-concentration, citrate free (40 mg/0.4 mL) version. The launch of the new higher concentration formulation (40 mg/0.4 mL) (compared to HADLIMA^® 40 mg/0.8 mL) offers physicians and patients with more options for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis, ankylosing spondylitis (AS), psoriatic arthritis, adult Crohn's disease, ulcerative colitis, adult and adolescent hidradenitis suppurativa, plaque psoriasis, adult and pediatric uveitis.^¹

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

The close: Wall Street boasts fresh records as inflation data fuels rate-cut bets

Chevron tops Tesla as most-shorted stock in April, says Hazeltree

The close: Nasdaq at record high after Fed chair’s comments but TSX dips for third day

The close: S&P 500, TSX slip as investors await inflation data; meme rally reignites

report on business

Shopify executive earned US$76-million in 2023, far outpacing CEO’s compensation

inside the market

Advantage Energy director buys as stock rallies

The close: S&P 500 higher but TSX slips as traders await key U.S. inflation data

inside the market

How pro money managers are balancing exposure to Canadian and U.S. stocks